Financial Comparison: Talphera (TLPH) vs. Its Rivals

Talphera (NASDAQ:TLPH – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Talphera to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares Talphera and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Talphera $30,000.00 -$14.29 million -3.36
Talphera Competitors $18.55 billion $3.23 billion 562.78

Talphera’s peers have higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Talphera has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Talphera’s peers have a beta of -0.04, indicating that their average share price is 104% less volatile than the S&P 500.

Profitability

This table compares Talphera and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talphera N/A -96.70% -53.18%
Talphera Competitors -2,398.26% -203.62% -15.08%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Talphera and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera 1 1 2 0 2.25
Talphera Competitors 7845 13797 25812 1039 2.41

Talphera presently has a consensus price target of $3.00, suggesting a potential upside of 231.13%. As a group, “Pharmaceuticals” companies have a potential upside of 23.69%. Given Talphera’s higher possible upside, equities research analysts clearly believe Talphera is more favorable than its peers.

Institutional & Insider Ownership

37.7% of Talphera shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Talphera peers beat Talphera on 8 of the 13 factors compared.

About Talphera

(Get Free Report)

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.